Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.76 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.56 |
| ▸ | SHBG | P04278 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Algestone Acetophenide SCHEMBL3039564 | 1.00 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetophenide SCHEMBL1649218 | 1.00 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetonide SCHEMBL42582 | 0.87 | CYP17A1 (0.85) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL7993136 | 0.87 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL29500568 | 0.87 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL4541005 | 0.87 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL29409283 | 0.87 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL4539514 | 0.87 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL151266 | 0.77 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL19505758 | 0.76 | SHBG (0.53) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3501543-A1 | METHOD FOR MANUFACTURING VAGINAL DRUG DELIVERY SYSTEMS USING A THREE DIMENSIONAL PRINTER | Delim Cosmetics & Pharma S.r.l. (IT) | 2019-06-26 | — | — | EP | claimed |
| CN-106866777-B | The preparation method of algestone acetophenide | 杭州弘任医药科技有限公司 | 2019-05-24 | — | — | CN | claimed |
| CN-106866777-A | The preparation method of algestone acetophenide | 杭州弘任医药科技有限公司 | 2017-06-20 | — | — | CN | claimed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | claimed |
| US-20120189599-A1 | MEDICATION FOR ORAL ADMINISTRATION, COMPRISING AT LEAST ONE ESTROGEN AND/OR AT LEAST ONE GESTAGEN AND AT LEAST ONE PROBIOTIC BACTERIAL STRAIN | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | claimed |
| EP-2116249-B1 | Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates | Bayer Pharma AG (DE) | 2012-05-02 | — | — | EP | claimed |
| EP-1888077-B1 | PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND/OR ESTROGENS AND 5-METHYL-(6S)-TETRAHYDROFOLATE | BAYER SCHERING PHARMA AG (DE) | 2009-04-29 | — | — | EP | claimed |
| US-20080280861-A1 | Method of Female Contraception and a Kit For Use Therein | PANTARHEI BIOSCIENCE B.V. (NL) | 2008-11-13 | — | — | US | claimed |
| US-20080234240-A1 | Extended Use Combination Comprising Estrogens And Progestins | SCHERING AG (DE) | 2008-09-25 | — | — | US | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0136011-B1 | A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor | PRE JAY HOLDINGS LTD (CA) | 1997-01-22 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-4826831-A | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | PRE JAY HOLDINGS LIMITED (CA) | 1989-05-02 | — | — | US | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |